Clinical Efficacy of Conservative Treatment in Female Patients With Plevic Congestion Syndrome

Interregional Clinical Diagnostic Center, Russia2 sites in 1 country83 target enrollmentDecember 28, 2019

ConditionsPelvic Congestion Syndrome

InterventionsDaflon

DrugsDaflon

Overview

Phase: N/A
Intervention: Daflon
Conditions: Pelvic Congestion Syndrome
Sponsor: Interregional Clinical Diagnostic Center, Russia
Enrollment: 83
Locations: 2
Primary Endpoint: Pelvic Varicose Veins Questionnaire
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The article presents the results of a randomized, placebo-controlled study of the conservative treatment with Daflon (Detralex) in female patients with Pelvic congestion syndrome .

Registry

clinicaltrials.gov

Start Date

December 28, 2019

End Date

March 28, 2020

Last Updated

5 years ago

Study Type

Observational

Sex

Female

Investigators

Sponsor

Interregional Clinical Diagnostic Center, Russia

Responsible Party

Principal Investigator

Akhmetzianov Rustem

Principal Investigator

Interregional Clinical Diagnostic Center, Russia

Eligibility Criteria

Inclusion Criteria

•The presence of pelvic varicose veins verified by transvaginal and transabdominal duplex ultrasound scanning

Exclusion Criteria

•Severe disease of the gastrointestinal tract or hematopoietic system
•Terminal stage of cardiovascular, respiratory, renal or hepatic failure
•Grade IV malignancy
•Peripheral artery disease (PAD) of the lower extremities, any type of diabetes, or mental disease.
•Pregnant women at any gestational age, women who gave birth less than 12 months ago, and breastfeeding mothers.